Jun 20, 2023 8:30 am EDT MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
Jun 9, 2023 9:00 am EDT MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
Jun 8, 2023 11:30 am EDT Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees
Jun 5, 2023 8:00 am EDT Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
May 25, 2023 4:00 pm EDT MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
May 25, 2023 8:00 am EDT MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
May 24, 2023 7:00 am EDT MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting